Citation Impact
Citing Papers
Binding of tissue plasminogen activator to human umbilical vein endothelial cells
1987
Intracranial hemorrhage in association with thrombolytic therapy: Incidence and clinical predictive factors
1992
Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: Results of the rt-PA-APSAC patency study (TAPS)
1992
Inflammation and Alzheimer's disease
2000 Standout
Mechanisms of arterial thrombosis in nonparallel streamlines: platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model.
1989
TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION
1988
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels
1998 Standout
Why Don't Physicians Follow Clinical Practice Guidelines?
1999 Standout
Ischemic stroke and intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction: A risk-benefit analysis
1992
Delayed graft function in kidney transplantation
2004 Standout
Bleeding during Thrombolytic Therapy for Acute Myocardial Infarction: Mechanisms and Management
1989
Mechanisms Underlying Inflammation in Neurodegeneration
2010 Standout
Prospects for Cardiovascular Research
2001 StandoutNobel
Lack of impact of early catheterization and fibrin specificity on bleeding complications after thrombolytic therapy
1993
The Use of Contrast-Enhanced Magnetic Resonance Imaging to Identify Reversible Myocardial Dysfunction
2000 Standout
Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator
1989
Irregular coronary lesion morphology after thrombolysis predicts early clinical instability
1991
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris
1995 Standout
Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction
1992 StandoutNature
A Prospective Natural-History Study of Coronary Atherosclerosis
2011 Standout
Regional myocardial blood flow and metabolism at rest in mildly symptomatic patients with hypertrophic cardiomyopathy
1989
Nonresolving Inflammation
2010 Standout
Structural and functional features of central nervous system lymphatic vessels
2015 StandoutNature
Acute Renal Failure
1996 Standout
Antioxidants and Atherosclerotic Heart Disease
1997 Standout
Association of Fibrinogen, C-reactive Protein, Albumin, or Leukocyte Count With Coronary Heart Disease
1998 Standout
Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
1988
GISSI-2 and the heparin controversy
1990
Hemodynamic Shear Stress and Its Role in Atherosclerosis
1999 Standout
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
1992 Standout
Cholesterol Reduction in Cardiovascular Disease — Clinical Benefits and Possible Mechanisms
1995
Angiographic assessment of the culprit coronary artery lesion before acute myocardial infarction
1990
Initiation of Platelet Adhesion by Arrest onto Fibrinogen or Translocation on von Willebrand Factor
1996 Standout
Atherosclerosis — An Inflammatory Disease
1999 Standout
Alzheimer's Disease
2010 Standout
Angiographic progression of coronary artery disease and the development of myocardial infarction
1988
Myocardial Reperfusion Injury
2007 Standout
Chest pain during daily life in patients with hypertrophic cardiomyopathy: an ambulatory electrocardiographic study
1996
Thrombolysis and Angioplasty in Myocardial Infarction (TAMI-1) trial: Influence of infarct location on arterial patency, left ventricular function and mortality
1989
Hypertrophic Cardiomyopathy
2002 Standout
Coronary lesion morphology in acute myocardial infarction: Demonstration of early remodeling after streptokinase treatment
1990
Value of gadolinium-diethylene-triamine pentaacetic acid dynamics in magnetic resonance imaging of acute myocardial infarction with occluded and reperfused coronary arteries after thrombolysis
1990
Tomographic imaging using the nonlinear response of magnetic particles
2005 StandoutNature
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
2001 Standout
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
1992 Standout
Activation of the terminal complement cascade in renal infarction
1995
Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock
1991
Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy Men
1997 Standout
C-Reactive Protein and Other Markers of Inflammation in the Prediction of Cardiovascular Disease in Women
2000 Standout
Hypertrophic Cardiomyopathy and Sudden Death
1988
The pathogenesis of atherosclerosis: a perspective for the 1990s
1993 StandoutNature
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
2005 Standout
A Randomized Trial of Intravenous Tissue Plasminogen Activator for Acute Myocardial Infarction with Subsequent Randomization to Elective Coronary Angioplasty
1987
Heparin plus Alteplase Compared with Heparin Alone in Patients with Submassive Pulmonary Embolism
2002 Standout
Bias in meta-analysis detected by a simple, graphical test
1997 Standout
Delirium in Mechanically Ventilated Patients
2001 Standout
Standardized Bleeding Definitions for Cardiovascular Clinical Trials
2011 Standout
Plasminogen activator inhibitors
1987
Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes
1998 Standout
Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
1994 Standout
Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction. Results of thrombolysis and angioplasty in myocardial infarction--phase 5 randomized trial. TAMI Study Group.
1991
The Coronary Angiogram and Its Seminal Contributions to Cardiovascular Medicine Over Five Decades
2002
C-Reactive Protein Colocalizes With Complement in Human Hearts During Acute Myocardial Infarction
1997
Tissue Plasminogen Activator for Acute Ischemic Stroke
1995 Standout
A prospective, randomized trial comparing combination half-dose tissue-type plasminogen activator and streptokinase with full-dose tissue-type plasminogen activator. Kentucky Acute Myocardial Infarction Trial (KAMIT) Group.
1991
Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.
1987 Standout
INFLAMMATION AND ALZHEIMERS DISEASE
2000
Coronary Thrombolysis for Evolving Myocardial Infarction
1984
Identification of the target self-antigens in reperfusion injury
2006
Intravenous short-term infusion of streptokinase in acute myocardial infarction.
1983
Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation
2001 Standout
Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction.
1988
Paradoxic elevation of fibrinopeptide A after streptokinase: Evidence for continued thrombosis despite intense fibrinolysis
1987
Coronary thrombolysis--clinical guidelines and public policy: results of an Ontario practitioner survey.
1990
Quantitative analysis of narrowings of intramyocardial small arteries in normal hearts, hypertensive hearts, and hearts with hypertrophic cardiomyopathy.
1987
Inflammation and Atherosclerosis
2002 Standout
Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularization
1997 Standout
Factors influencing probability of reperfusion with intracoronary ostial infusion of thrombolytic agent in patients with acute myocardial infarction.
1985
Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells.
1990 StandoutNobel
In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin
1990
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
1995 Standout
Regional myocardial blood flow and glucose utilization in symptomatic patients with hypertrophic cardiomyopathy.
1993
Pexelizumab, an Anti-C5 Complement Antibody, as Adjunctive Therapy to Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction
2003
Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial.
1992
Circulating Adhesion Molecules VCAM-1, ICAM-1, and E-selectin in Carotid Atherosclerosis and Incident Coronary Heart Disease Cases
1997
An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction
1993 Standout
IMPROVED SURVIVAL AFTER EARLY THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION
1985
EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION
1986 Standout
ACUTE PULMONARY EMBOLISM TREATED WITH TISSUE PLASMINOGEN ACTIVATOR
1986
Psychiatric Morbidity during the Early Phase of Coronary Care for Myocardial Infarction: Association with Cardiac Diagnosis and Outcome*
1992
Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty
1994 Standout
Hypertrophic Cardiomyopathy
1987
Myocardial Infarction and Apoptosis After Myocardial Ischemia and Reperfusion
1998
Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology.
1994
Time from onset of symptoms to thrombolytic therapy: A major determinant of myocardial salvage in patients with acute transmural infarction
1985
Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity
1988
Tissue Plasminogen Activator Reduces Neurological Damage After Cerebral Embolism
1985 Science
Severe functional limitation in patients with hypertrophic cardiomyopathy and only mild localized left ventricular hypertrophy
1986
Works of D Mathey being referenced
Early accumulation of the terminal complement-complex in the ischaemic myocardium after reperfusion
1994
Transluminal recanalization of coronary artery thrombosis: a preliminary report of its application in cardiogenic shock
1980
Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium.
1986
Quantitative measurement of SC5b-9 and C5b-9(m) in infarcted areas of human myocardium
1990
Percutaneous transluminal coronary recanalization: Procedure, results, and acute complications
1981
Incomplete lysis of thrombus in the moderate underlying atherosclerotic lesion during intracoronary infusion of streptokinase for acute myocardial infarction: quantitative angiographic observations.
1986
Myocardial Thallium201imaging in hypertrophic obstructive cardiomyopathy
1981
Changes in left ventricular function after intracoronary streptokinase infusion in clinically evolving myocardial infarction
1981
RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION
1985
[Correlation between myocardial Thallium-201 kinetics, myocardial lactate metabolism and coronary angiographic findings in hypertrophic cardiomyopathy (author's transl)].
1980